It takes U.S. adults, on average, a decade or more to seek behavioral health services. There are many reasons for this, including insurance barriers and lack of services, but a significant one is the stigma and discrimination related to their situation. Stigma is one of the biggest barriers to recovery, including the stigma associated with medications for opioid use disorder (MOUD). A common misconception – even amongst some peer and recovery communities – is that medications “replace one drug with another.” Some still inaccurately claim that drug use is a “moral failing” or the result of a lack of “mental fortitude” or “willpower.” These perspectives result in harmful attitudes and behaviors that negatively impact recovery and increase the deadliness of opioid addiction. Folks in recovery may avoid, reject, or move away from treatment due to shame or poor delivery. Providers may hesitate to offer MOUD, and communities may oppose treatment programs in local care facilities.
While there are many paths to recovery and everyone’s needs differ, medication is a vital, evidence-based recovery tool, which serves as a life-saving bridge to stability for many. The most common medications used to treat opioid use disorder are methadone, buprenorphine, and naltrexone, which are all FDA-approved for that purpose.. They prevent withdrawal and craving symptoms and have been reliably shown to lower the risk of overdose and improve recovery outcomes. Scientific research suggests MOUD is the “gold standard” for treatment (Connery, 2015; Moore et al., 2019; cited in Moore et al., 2026). However, many still perceive them negatively. Federal funding plays an important role in making these treatments available and, although Health and Human Services Secretary Robert F. Kennedy Jr. has challenged the use of some prescription drugs used to treat behavioral health challenges, the Make America Healthy Again (MAHA) initiative endorses MOUD alongside abstinence-based approaches.
MOUD Stigma Negatively Impacts Recovery
MOUD is also often dismissed as “replacing one drug with another,” which can lead to stigmatizing experiences. Many 12-step recovery communities have historically maintained a position that MOUD is incompatible with their definition of “total abstinence,” resulting in those receiving MOUD feeling unwelcome or stigmatized. They may even be even prohibited from holding service positions or identifying as “sober” as a result. As the dialogue on MOUDs has advanced, there have been some shifts. For instance, Narcotics Anonymous (NA) World Services has clarified that their only requirement for membership is a “desire to stop using,” but also acknowledges that group participants may have very strong feelings about MOUD. They recommend that folks utilizing MOUD may need to try several different NA groups before finding one that best suits their needs.
The World Health Organization (2019) has long defined addiction as “a chronic disease. It affects a person’s brain and changes their behaviour so that they act in a way that harms them. They become unable to stop taking a drug or engaging in a certain behaviour (gambling, shopping, online gaming) to the point where it becomes harmful.” Because this disease often begins with a choice to use drugs, and because some are able to use drugs without addiction, some still hold to the belief that addiction is a moral failing or lack of willpower.
As a contrasting example, the Center for Disease Control (2024) reports that heart disease has been the number one killer (nearly 1 in 3 deaths) in the U.S. since 1950. Certain choices like diet and lifestyle can increase risk of heart disease, but a “sweet tooth” is not seen as a moral failure, and few providers would deny medication to manage a disease because of it. Lifestyle is often impacted by environment, access, and resources, not just choice or willpower, and diet and exercise alone are likely not enough to remedy the disease. Similar stigmatizing misconceptions remain around addiction, which can increase shame, isolation, and even impact the delivery of lifesaving, evidence-based treatments like MOUD.
MOUD Looks Different for Everyone
The medications used to treat addiction to opioids like heroin, fentanyl, and prescription pain killers vary, and this leads to some confusion and stigmatization as well. Depending on a person’s needs, a physician may prescribe one of three common medications: methadone, buprenorphine, or naltrexone. Both methadone and buprenorphine are opioids, binding to the same brain receptors that reduce symptoms without causing a “high” through prescribed use. Naltrexone, an opioid antagonist, works by blocking opioid receptors in the brain. Because of the possibility of misuse, these medications – methadone especially – are highly supervised and regulated, which leads to stigma of its own.
The phrase “Liquid Handcuffs,” popularized by Helen Redmond’s book of the same title, is often used to describe the strict, in-person clinic visits required for methadone treatment, and the rigid and highly regulated system can create challenges. Rules like frequent drug testing and limits on take-home doses make it difficult for patients trying to balance treatment with work, family, and other responsibilities. “Handcuffs” are also an appropriate metaphor, echoing the stigmatizing perception of wrong-doing and suggesting that treatment is a form of punishment.
This stigma also impacts availability of services due to public reaction and even the attitudes of – and toward – some healthcare providers. MOUD faces “intervention stigma” (Madden et al., 2022), meaning people are judged or discriminated against for even providing these treatments, which, in turn, may limit community support of treatment sites, prohibiting ease of access to care and increasing the likelihood of overdose.
MOUD and Federal Policy
Federal funding and support also play a critical role in the availability and legitimacy of these life-saving treatment options. Some behavioral health recovery treatments have been challenged by the current administration, including anti-anxiety medications. Fortunately, support remains for MOUD. Health and Human Services Secretary Robert F. Kennedy Jr. and the Make America Health Again (MAHA) initiative does suggest a preference for prevention and holistic approaches, primarily diet and exercise, which can be helpful to recovery.
While current information is difficult to find, the Senate FY2026 funding bills suggested allocation of $10.7 million towards opioid treatment programs – only slightly lower than the $11 million allocated in 2025. Federal funding, mainly through Substance Abuse and Mental Health Services Administration (SAMHSA) grants and Medicaid, helps make opioid treatment more accessible. Funds support the use of evidence-based care, help reduce overdose deaths, and aid long-term recovery by expanding access to medications (like those detailed above) as well as life-saving tools like naloxone. MOUD implementation into criminal legal system settings is also recommended by SAMHSA and the American Civil Liberties Union (ACLU, 2021; SAMHSA, 2024) (cited in Moore et al., 2026).
A recent executive order from the White House (2026) stated, “The framework for addiction treatment should parallel that of other chronic diseases – utilizing evidence-based care, scientific advancement, continuous support, and community connection.” With this in mind, we can hope that support for MOUD will continue in the foreseeable future. Because supporting multiple pathways to recovery is critical to continued success, it’s good to know that MOUD remains an option.
Sources
Erin F. Madden, Kristin K. Barker, Joshua Guerra, Corey Villanueva, Sandra H. Sulzer. “Variation in intervention stigma among medications for opioid use disorder.” SSM - Qualitative Research in Health, Volume 2, 2022. https://doi.org/10.1016/j.ssmqr.2022.100161.
John Moore, Tanya Renn, Christopher Veeh, Sara Beeler. “Differences in MOUD receipt by legal referral type in outpatient treatment.” Journal of Substance Use and Addiction Treatment, Volume 184, 2026. https://doi.org/10.1016/j.josat.2026.209888.

